Stock Falls After Mixed MariTide Trial Update

benzinga.com/trading-ideas/movers/25/06/46062693/amgen-amgn-stock-falls-after-mixed-maritide-trial-update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.
What To Know: The therapy, a long-acting, peptide-antibody conjugate…

This story appeared on benzinga.com, 2025-06-23 20:24:47.
The Entire Business World on a Single Page. Free to Use →